Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

11.85USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$11.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,317
52-wk High
$12.15
52-wk Low
$6.60

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Announces Commercial Availability Of Mirataz
Monday, 9 Jul 2018 08:31am EDT 

July 9 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES COMMERCIAL AVAILABILITY OF MIRATAZ® (MIRTAZAPINE TRANSDERMAL OINTMENT) TO VETERINARIANS IN THE UNITED STATES.KINDRED BIOSCIENCES - MIRATAZ FOR MANAGEMENT OF WEIGHT LOSS IN CATS IS COMMERCIALLY AVAILABLE TO VETERINARIANS IN U.S..  Full Article

Kindred Biosciences Announces Termination Of Its At-The-Market Equity Offering Program
Wednesday, 20 Jun 2018 04:01pm EDT 

June 20 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES THE TERMINATION OF ITS AT-THE-MARKET EQUITY OFFERING PROGRAM.KINDRED BIOSCIENCES - TERMINATION OF "AT--MARKET" EQUITY OFFERING PROGRAM.KINDRED BIOSCIENCES INC - KINDREDBIO WILL MAKE NO FURTHER SALES OF SHARES UNDER ATM FACILITY BETWEEN JUNE 20, 2018 AND EFFECTIVE DATE.KINDRED BIOSCIENCES INC - OFFICIAL TERMINATION OF ATM FACILITY WILL BE EFFECTIVE AS OF JUNE 30, 2018.  Full Article

Kindred Biosciences Reports Q1 Loss Per Share $0.36
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.KINDRED BIOSCIENCES - FOR 2018 CALENDAR YEAR, REITERATES PREVIOUS GUIDANCE FOR OPERATING. EXPENSES TO BE IN RANGE OF $44 MILLION TO $48 MILLION, EXCLUDING ITEMS.AS OF MARCH 31, 2018, KINDREDBIO HAD $70.8 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.  Full Article

Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement
Monday, 7 May 2018 07:10am EDT 

May 7 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING.KINDRED BIOSCIENCES INC - CO MAY OFFER AND SELL SHARES HAVING AN AGGREGATE OFFERING PRICE OF UP TO $50.0 MILLION.  Full Article

Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats
Monday, 7 May 2018 07:00am EDT 

May 7 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS.KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS.KINDRED BIOSCIENCES INC - U.S. FOOD AND DRUG ADMINISTRATION'S CENTER FOR VETERINARY MEDICINE APPROVED MIRATAZ FOR MANAGEMENT OF WEIGHT LOSS IN CATS.  Full Article

Kindred Biosciences Inc Files For Mixed Shelf Of Up To $150 Million
Thursday, 18 Jan 2018 12:38pm EST 

Jan 18 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​.  Full Article

KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
Thursday, 21 Dec 2017 08:02am EST 

Dec 21 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™.KINDRED BIOSCIENCES INC - EMA HAS ACCEPTED SUBMISSION FOR REVIEW, WITH OFFICIAL ACCEPTANCE DATE OF DECEMBER 21, 2017.KINDRED BIOSCIENCES INC - EXECUTED NATIONAL DISTRIBUTION DEALS WITH MWI VETERINARY SUPPLY CO. & DIRECT VET MARKETING, INC. D/B/A VETS FIRST CHOICE.  Full Article

KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
Monday, 4 Dec 2017 08:02am EST 

Dec 4 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES.KINDRED BIOSCIENCES INC - ‍BASED ON PRELIMINARY REVIEW OF SAFETY DATA, DRUG ZIMETA APPEARS TO BE WELL TOLERATED ​.KINDRED BIOSCIENCES INC - CO ANTICIPATES SUBMITTING EFFECTIVENESS TECHNICAL SECTION OF NEW ANIMAL DRUG APPLICATION IN EARLY 2018​.  Full Article

Kindred Biosciences posts Q3 loss of $0.29 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc :Kindred biosciences announces third quarter 2017 financial results.Q3 loss per share $0.29.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences gets approval from FDA for new animal drug application
Tuesday, 4 Oct 2016 04:01pm EDT 

Kindred Biosciences Inc : Kindred Biosciences receives approval of effectiveness technical section from fda for zimeta new animal drug application . Kindredbio is in process of responding to first round of review by fda on safety technical section .Kindred Biosciences Inc says expects approval of Zimeta in first half of 2017 if FDA review process is rapid.  Full Article

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS